Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

BACKGROUND The hallmark of severe hemophilia (A or B) is recurrent bleeding into joints and soft tissues with progressive joint damage, despite on-demand treatment. Prophylaxis has long been used, but not universally adopted, because of medical, psychosocial, and cost controversies. OBJECTIVES To determine the effectiveness of clotting factor concentrate prophylaxis in managing previously-treated individuals with hemophilia A or B. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. In addition, we searched MEDLINE and Embase and online trial registries. Most recent search of Group's Coagulopathies Trials Register: 24 February 2021. SELECTION CRITERIA Randomised controlled trials (RCTs) and quasi-RCTs evaluating people with hemophilia A or hemophilia B, who were previously treated with clotting factor concentrates to manage their hemophilia. DATA COLLECTION AND ANALYSIS Two authors independently reviewed trials for eligibility, assessed risk of bias and extracted data. The authors used the GRADE criteria to assess the certainty of the evidence. MAIN RESULTS Ten trials (including 608 participants) were eligible for inclusion. Eight of the trials (477 participants) had arms comparing two or more prophylactic regimens to one another and four of the trials (n = 258) compared prophylaxis to on-demand treatment (two trials had multiple arms and were included in both comparisons). Comparison of two or more prophylactic regimens For trials comparing one prophylaxis regimen to another, given the heterogeneity of the data, none of the data were pooled for this comparison. Considering the individual trials, three trials reported the primary outcome of joint bleeding, and none showed a dfference between dosing regimens (low-certainty evidence). For the secondary outcome of total bleeding events, prophylaxis with a twice-weekly regimen of FIX likely results in reduced total bleeds compared to a once-a-week regimen of the same dose, mean difference (MD) 11.2 (5.81 to 16.59) (one trial, 10 participants, low-certainty evidence). Transient low-titer anti-FVIII inhibitors were reported in one of the trials. Blood-transmitted infections were not identified. Other adverse events reported include hypersensitivity, oedema, and weight gain. These were, however, rare and unrelated to study drugs (very low-certainty evidence). Comparison of prophylactic and on-demand regimens Four of the trials (258 participants) had arms that compared prophylaxis to on-demand treatment. Prophylaxis may result in a large decrease in the number of joint bleeds compared to on-demand treatment, MD -30.34 (95% CI -46.95 to -13.73) (two trials, 164 participants, low-certainty evidence). One of these trials (84 participants) also reported the long-term effects of prophylaxis versus on-demand therapy showing improved joint function, quality of life, and pain; but no differences between groups in joint structure when assessed by magnetic resonance imaging (MRI). In one trial (84 participants) validated measures for joint health and pain assessment showed that prophylaxis likely improves joint health compared to an on-demand regimen with an estimated change difference of 0.94 points (95% CI 0.23 to 1.65) and improves total pain scores, MD -17.20 (95% CI -27.48 to -6.92 (moderate-certainty evidence). Two trials (131 participants) reported that prophylaxis likely results in a slight increase in adverse events, risk ratio 1.71 (1.24 to 2.37) (moderate-certainty evidence). No inhibitor development and blood-transmitted infections were identified. Overall, the certainty of the body of evidence was judged to be low because of different types of bias that could have altered the effect.   AUTHORS' CONCLUSIONS: There is evidence from RCTs that prophylaxis, as compared to on-demand treatment, may reduce bleeding frequency in previously-treated people with hemophilia. Prophylaxis may also improve joint function, pain and quality of life, even though this does not translate into a detectable improvement of articular damage when assessed by MRI.  When comparing two different prophylaxis regimens, no significant differences in terms of protection from bleeding were found. Dose optimization could, however, result in improved efficacy. Given the heterogeneity of the data, pooled estimates were not obtained for most comparisons.  Well-designed RCTs and prospective observational controlled studies with standardised definitions and measurements are needed to establish the optimal and most cost-effective treatment regimens.

[1]  M. Bertolet,et al.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia. , 2020, Blood advances.

[2]  O. Stasyshyn,et al.  Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. , 2020, Blood.

[3]  A. Iorio,et al.  Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A , 2020, Annals of Hematology.

[4]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  R. Gooding,et al.  Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B , 2020, British journal of haematology.

[6]  G. Spotts,et al.  Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis , 2020, Thrombosis and Haemostasis.

[7]  G. Kenet,et al.  Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Oldenburg,et al.  Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  J. Astermark,et al.  Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. , 2019, Blood.

[10]  C. Hermans,et al.  Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data , 2019, Blood.

[11]  T. Porstmann,et al.  Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results , 2019, Blood.

[12]  E. Santagostino,et al.  Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study , 2019, Blood.

[13]  V. Jiménez‐Yuste,et al.  Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial , 2019, Blood.

[14]  P. Kuebler,et al.  Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program , 2019, Journal of thrombosis and haemostasis : JTH.

[15]  S. Kessabi,et al.  Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII) , 2019, The Patient - Patient-Centered Outcomes Research.

[16]  A. Iorio,et al.  Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A , 2019, Annals of Hematology.

[17]  A. Tulaar,et al.  Comparison of the efficacy and safety of 12‐month low‐dose factor VIII tertiary prophylaxis vs on‐demand treatment in severe haemophilia A children , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  Depei Wu,et al.  Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  R. Klamroth,et al.  Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial , 2019, Research and practice in thrombosis and haemostasis.

[20]  E. Santagostino,et al.  Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial) , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  I. Pabinger,et al.  Prophylaxis with Extended Dosing of BAY94-9027 Decreases Overall and Joint Bleeding Rates with Consistent Consumption for Over 4 Years of Treatment , 2019, Science meets clinical practice.

[22]  Klamroth Robert,et al.  Results from a Phase 3, Randomized, Multicenter Study of Rurioctocog alfa Pegol PK-Guided Prophylaxis Targeting 2 FVIII Trough Levels in Patients with Severe Hemophilia a (Propel Study) , 2019, Hämostaseologie.

[23]  J. Oldenburg,et al.  The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  B. Kerlin,et al.  Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study , 2018, Blood.

[25]  M. Simpson,et al.  Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension , 2018, Blood.

[26]  I. Pabinger,et al.  Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension , 2018, Blood.

[27]  E. Santagostino,et al.  Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials) , 2018, Blood.

[28]  Mark P Smith,et al.  Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A , 2018, Blood.

[29]  P. Holme,et al.  Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study , 2018, Blood.

[30]  V. Jiménez‐Yuste,et al.  A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A , 2018, Journal of thrombosis and haemostasis : JTH.

[31]  J. Oldenburg,et al.  Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[32]  G. Dolan,et al.  Value of prophylaxis vs on‐demand treatment: Application of a value framework in hemophilia , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  S. Lalezari,et al.  BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study , 2017 .

[35]  J. Oldenburg,et al.  Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study , 2017 .

[36]  J. Oldenburg,et al.  Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) , 2017 .

[37]  C. Peterfy,et al.  Effect of late prophylaxis in hemophilia on joint status: a randomized trial , 2017, Journal of thrombosis and haemostasis : JTH.

[38]  M. Wang,et al.  PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleeding , 2017, Haemophilia.

[39]  C. Thornburg,et al.  Treatment adherence in hemophilia , 2017, Patient preference and adherence.

[40]  V. Jiménez‐Yuste,et al.  The pharmacokinetics and pharmacodynamics of single‐dose and multiple‐dose recombinant activated factor VII in patients with haemophilia A or B , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[41]  A. Liddle,et al.  Evidence-Based Management of the Knee in Hemophilia , 2017, JBJS reviews.

[42]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[43]  B. Ploeger,et al.  Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  I. Pabinger,et al.  Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII , 2017, Journal of thrombosis and haemostasis : JTH.

[45]  K. Fischer,et al.  Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. , 2017, The Lancet. Haematology.

[46]  A. Neff,et al.  Pilot randomized, non‐inferiority, cross‐over trial of once‐weekly vs. three times‐weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A , 2017, Haemophilia.

[47]  M. Shima,et al.  Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product , 2017, International Journal of Hematology.

[48]  T. Humphries,et al.  Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study , 2016 .

[49]  F. Horling,et al.  Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α , 2016 .

[50]  D. Raunig,et al.  SPINART study: validation of the extended magnetic resonance imaging scale for evaluation of joint status in adult patients with severe haemophilia A using baseline data , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[51]  K. Wyrwich,et al.  Changes in health‐related quality of life with treatment of longer‐acting clotting factors: results in the A‐LONG and B‐LONG clinical studies , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  J. Oldenburg,et al.  Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[53]  J. Oldenburg,et al.  Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[54]  K. Fischer,et al.  pharmacokinetics of Bay 94-9027, a Pegylated B-domain-deleted recombinant factor Viii with an extended half-life, in children, adolescents, and adults with severe hemophilia A , 2016 .

[55]  C. Négrier,et al.  Recombinant long‐acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[56]  B. Ewenstein,et al.  Pro‐ and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  A. Regnault,et al.  Improvement in health‐related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half‐life recombinant FIX product , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[58]  S. Goodman,et al.  Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research , 2016, Clinical trials.

[59]  T. Dutta,et al.  A randomized study of very low‐dose factor VIII prophylaxis in severe haemophilia – A success story from a resource limited country , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[60]  J. Oldenburg,et al.  Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[61]  E. Santagostino,et al.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. , 2016, Blood.

[62]  R. Ward,et al.  Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000–2010) , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[63]  D. Perry,et al.  Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[64]  S. Lukyanov,et al.  Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B , 2015 .

[65]  S. Kelkar,et al.  Patterns of Prior Treatment and Bleeds Among Patients with Severe Hemophilia a: Impact on Frequency of Dosing with Bay 81-8973 in the Leopold I Trial , 2015 .

[66]  S. Lukyanov,et al.  Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B , 2015 .

[67]  R. Klamroth,et al.  Characteristics of Patients without Bleeding in a Pivotal Trial of Extended Half-Life, Pegylated, Full-length Recombinant Factor VIII (BAX 855) in the Treatment of Hemophilia A , 2015 .

[68]  R. Klamroth,et al.  Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) , 2015 .

[69]  S. Garger,et al.  Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[70]  S. Polinder,et al.  The “OPTI-CLOT” trial , 2015, Thrombosis and Haemostasis.

[71]  J. Mahlangu,et al.  Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A , 2015, Journal of thrombosis and haemostasis : JTH.

[72]  P. Chowdary,et al.  Improved Health status of Haemophilia B Patients treated with Nonacog Beta Pegol, a new Glycopegylated recombinant fix product with Prolonged Half-Life , 2015 .

[73]  S. Lethagen,et al.  Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial , 2015, Journal of thrombosis and haemostasis : JTH.

[74]  C. Santoro,et al.  Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study , 2015, Thrombosis and Haemostasis.

[75]  C. Joch,et al.  Efficacy, safety and pharmacokinetic results of a phase II/III, multicentre, double-blinded, randomized, cross-over study with a plasma-derived von Willebrand Factor/factor VIII concentrate (Voncento ®) in subjects with hemophilia A (the SWIFT-HA study) , 2015 .

[76]  T. Humphries,et al.  spinart 3-year Data: Patient-reported Benefits of Adult Prophylaxis Vs on-demand Treatment With Bayer's Sucrose-formulated Recombinant Factor Viii : pp065 , 2015 .

[77]  J. Mahlangu,et al.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) , 2015, Journal of thrombosis and haemostasis : JTH.

[78]  J. Oldenburg,et al.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. , 2014, Blood.

[79]  M. Ragni,et al.  Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance , 2014, Expert review of hematology.

[80]  J. Dumont,et al.  Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels , 2014, Journal of thrombosis and haemostasis : JTH.

[81]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[82]  L. Valentino,et al.  ADVATE prophylaxis: post hoc analysis of joint bleeding episodes , 2014 .

[83]  O. Stasyshyn,et al.  Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open‐label, uncontrolled, multicentre, phase III study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[84]  W. B. Knowlton,et al.  Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326 ) , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[85]  J. Epstein,et al.  Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[86]  T. Humphries,et al.  spinart trial 3-year results: improved quality of life in adults using prophylaxis with Bayer's sucrose-formulated recombinant factor Viii : Coa34 , 2014 .

[87]  S. Mahadevan,et al.  low-dose Factor Viii prophylaxis in children with severe hemophilia , 2014 .

[88]  L. Valentino,et al.  Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[89]  A. Coppola,et al.  Patient characteristics that influence efficacy of prophylaxis with rFVIII‐FS three times per week: a subgroup analysis of the LIPLONG study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[90]  J. Epstein,et al.  Improvement in health‐related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[91]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[92]  O. Stasyshyn,et al.  Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[93]  M. Carr,et al.  Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[94]  J. Windyga,et al.  Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[95]  S. Antunes,et al.  Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[96]  L. Valentino,et al.  Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc) , 2013 .

[97]  P. Cortesi,et al.  Health‐related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti‐inhibitor complex concentrate: results from the Pro‐FEIBA study , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[98]  J. Oldenburg,et al.  Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B , 2013 .

[99]  S. Antunes,et al.  Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from AICC prophylaxis study , 2013 .

[100]  C. Kempton,et al.  Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.

[101]  J. Korth-Bradley,et al.  Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients , 2012 .

[102]  G. Di Minno,et al.  Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients , 2012, Thrombosis and Haemostasis.

[103]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[104]  P. Cortesi,et al.  Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. , 2011, The New England journal of medicine.

[105]  P. Cortesi,et al.  PSY47 Evaluating the Cross-over Effect on Health-related Quality of Life in a Randomized Cross-over Study of Hemophilia-A Patients , 2011 .

[106]  M. Ragni Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial , 2011, Expert review of hematology.

[107]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2011, The Cochrane database of systematic reviews.

[108]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[109]  R. Wu,et al.  Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[110]  C. Leissinger,et al.  Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study , 2010 .

[111]  L. Mantovani,et al.  A randomized clinical trial on prophylaxis vs. episodic treatment in children with haemophilia A: the ESPRIT study , 2010 .

[112]  R. Liesner,et al.  A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A , 2010, British journal of haematology.

[113]  M. Morfini,et al.  Efficacy and safety of secondary prophylactic vs. on‐demand sucrose‐formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13‐month crossover study , 2010, Journal of thrombosis and haemostasis : JTH.

[114]  G. Di Minno,et al.  Longer‐acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[115]  C. Leissinger,et al.  A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data , 2010 .

[116]  V. Jiménez‐Yuste,et al.  European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study , 2010 .

[117]  P. Mannucci,et al.  Effects of secondary prophylaxis started in adolescent and adult haemophiliacs , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[118]  H. Ehrlich,et al.  Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study , 2008, Acta Haematologica.

[119]  K. Kurnik,et al.  Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A , 2007, Thrombosis and Haemostasis.

[120]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[121]  C. Hay Prophylaxis in adults with haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[122]  J. Rich-Edwards,et al.  Central Venous Access Device Infections in Children With Hemophilia: A Comparison of Prophylaxis and Episodic Therapy , 2007, Journal of pediatric hematology/oncology.

[123]  H. Ehrlich,et al.  Evaluation of pharmacokinetics, efficacy and safety of Immunate® solvent detergent in previously treated patients with severe haemophilia A , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[124]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[125]  R. Ljung,et al.  Optimizing factor prophylaxis for the haemophilia population: where do we stand? , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[126]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[127]  V. Blanchette,et al.  North American prophylaxis studies for persons with severe haemophilia: background, rationale and design , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[128]  A. Gringeri Prospective controlled studies on prophylaxis: an Italian approach , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[129]  P. Giangrande,et al.  Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[130]  C. Bedrosian,et al.  Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. , 2001, Seminars in hematology.

[131]  F. Beek,et al.  Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia , 2001, British journal of haematology.

[132]  J. Astermark,et al.  Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized , 1999, British journal of haematology.

[133]  C. Kessler,et al.  When should prophylactic treatment in patients with haemophilia A and B start?— The German experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[134]  J. Lusher Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment? , 1997, Thrombosis and Haemostasis.

[135]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[136]  R. Ljung,et al.  Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[137]  N. Çetingül,et al.  Prophylactic therapy for hemophilia in a developing country, Turkey. , 1997, Pediatric hematology and oncology.

[138]  S. Böttger,et al.  Radiological score in paediatric haemophilic patients with early and late onset of factor VIII-prophylaxis. , 1996, Thrombosis and haemostasis.

[139]  W. Schramm,et al.  Socioeconomic impact of haemophilia care: results of a pilot study , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[140]  S. Teutsch,et al.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.

[141]  K. Khair,et al.  The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.

[142]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[143]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[144]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[145]  J. Oldenburg,et al.  Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. , 1992, Haemostasis.

[146]  M. Blombäck,et al.  Prophylaxis with factor concentrates in preventing hemophilic arthropathy. , 1991, The American journal of pediatric hematology/oncology.

[147]  H. Pettersson,et al.  RADIOLOGIC EVALUATION OF PROPHYLAXIS IN SEVERE HAEMOPHILIA , 1981, Acta paediatrica Scandinavica.

[148]  K. Schimpf,et al.  Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. , 2009, Scandinavian journal of haematology. Supplementum.

[149]  J. Mchardy,et al.  Twice weekly prophylactic therapy in haemophilia A. , 1977, Journal of clinical pathology.

[150]  F. Mandelli,et al.  Evaluation of prophylactic replacement therapy in haemophilia B. , 2009, Scandinavian journal of haematology.

[151]  M. Alderson,et al.  Prophylaxis in Haemophilia: A Double‐blind Controlled Trial , 1976, British journal of haematology.

[152]  Å. Ahlberg,et al.  HAEMOPHILIA PROPHYLAXIS IN SWEDEN , 1976, Acta paediatrica Scandinavica.

[153]  D. Ramsay,et al.  A trial of prophylactic replacement therapy in haemophilia and Christmas disease , 1973, Journal of clinical pathology.

[154]  M. Blombäck,et al.  Our experience in Sweden with prophylaxis on haemophilia. , 1970, Bibliotheca haematologica.

[155]  Å. Ahlberg Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.

[156]  F. Loth [Hemophilic arthropathy]. , 1962, Chirurgia narzadow ruchu i ortopedia polska.